CEL-SCI Corporation Share Price & Technical Analysis
CVM · $1.42 (-2.07%)
Healthcare / Biotechnology
$1.42
-2.07%
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation Sy…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-50% return in May, -27% avg return in past 3 year May month.
-94% return in 2026, 0% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 9% | -23% | -24% | -6% | -50% | – | – | – | – | – | – | – | -94% |
| 25 | -7% | -15% | -32% | 26% | -76% | 10% | 257% | 28% | -13% | -23% | 4% | -31% | 127% |
| 24 | 2% | -29% | -8% | -24% | -17% | -4% | -3% | -7% | -2% | -16% | -26% | -32% | -166% |
| 23 | 9% | -6% | -5% | -9% | 12% | 0% | -33% | -13% | -9% | 33% | 39% | 23% | 40% |
| 22 | -16% | -5% | -32% | -28% | 26% | 19% | -15% | 3% | -23% | 9% | -14% | -22% | -96% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$9.09M
P/E ratio
—
52W high
$13.48
52W low
$0.89
Volume
2,76,658
Beta
0.71
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is CEL-SCI Corporation share price today?
- CEL-SCI Corporation (CVM) last traded around $1.42 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CVM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CVM. Download the app for real-time alerts.
- How can I analyze CEL-SCI Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.